REC-4539 (LSD1 inhibitor)
Recursion (trial sponsor Exscientia AI Ltd, a Recursion subsidiary): company profile
Phase 1 registry
Since , the date of the source that reports this phase.
Summary
REC-4539 is a LSD1 inhibitor from Recursion (trial sponsor Exscientia AI Ltd, a Recursion subsidiary). It is being developed for small cell lung cancer and other select solid tumors. ClinicalTrials.gov lists it at Phase 1 (recruiting) under NCT07517198. The AI role named in the source is molecule design. Registry records: NCT07517198, Phase 1, recruiting, updated Jun 10, 2026. About the company, based in United States: Recursion OS pairs automated phenomic and other high-content biology at scale with machine learning, and since the November 2024 Exscientia combination also includes Exscientia's precision chemistry design. The latest dated source is from Jun 10, 2026.
Built only from the sources listed on this page.
Facts
- Company
- Recursion (trial sponsor Exscientia AI Ltd, a Recursion subsidiary)
- Indication
- Small cell lung cancer and other select solid tumors
- Therapeutic area
- Oncology
- AI role
- Molecule design
- Phase in the source
- Phase 1, as of Jun 10, 2026
- Phase source
- Registry
- Board column
- Phase 1
AI evidence
AI source: Company
“REC-4539: An LSD1 inhibitor AI-designed to address class-limiting toxicities”
Trial records
- NCT07517198 on ClinicalTrials.gov (opens in new tab) Phase 1 Recruiting Updated
Milestone timeline
-
NCT07517198 first posted on ClinicalTrials.gov
-
ClinicalTrials.gov record: Phase 1
-
NCT07517198 record updated
Phase 1, Recruiting
About Recursion Pharmaceuticals
Recursion OS pairs automated phenomic and other high-content biology at scale with machine learning, and since the November 2024 Exscientia combination also includes Exscientia's precision chemistry design.
Spot an error? Tell me and I'll fix it.